Equibles does not estimate personal net worth.
Get an email with a short summary when Madrigal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MDGL alertsBill Sibold is recorded as Board Member and CEO at Madrigal Pharmaceuticals, Inc. (MDGL). The newest filing on record that lists Bill Sibold as Board Member and CEO at Madrigal Pharmaceuticals, Inc. (MDGL) is dated April 28, 2026. Madrigal Pharmaceuticals, Inc. reported in an 8-K filed June 27, 2024 that Bill Sibold was appointed Class II Nominee, effective June 25, 2024. Madrigal Pharmaceuticals, Inc. reported in an 8-K filed September 13, 2023 that Bill Sibold was appointed member of the Board, effective September 8, 2023. Madrigal Pharmaceuticals, Inc. reported in an 8-K filed September 13, 2023 that Bill Sibold was appointed President and Chief Executive Officer, effective September 8, 2023. The proxy statement of Madrigal Pharmaceuticals, Inc. reports total compensation of $19,206,341 for Bill Sibold in fiscal 2025, including a base salary of $918,531. Disclosed compensation is on record for 3 fiscal years. Bill Sibold has spoken on 7 earnings calls and 2 other investor events across 1 company, most recently for Madrigal Pharmaceuticals, Inc. on August 11, 2026. Madrigal Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Madrigal Pharmaceuticals, Inc. includes Julian C. Baker (Chairman and Board Member), Mardi Dier (CFO), Brian J. Lynch (General Counsel) and 7 others.
“The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
“The Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") appointed Bill Sibold as the President and Chief Executive Officer of the Company, increased the Board size to nine and appointed Bill Sibold as a member of the Board, in each case effective as of 5:01 p.m. ET on September 8, 2023 (the "Start Date").”
“So at Madrigal, we've had excellent commercial growth since our launch in the first quarter of 2024. And we're focused very much on our two type priorities, which is building value for RISDFRA, getting RISDFRA to as many patients as we can, and building our pipeline so we can maintain our leadership position in MASH.”
“Before we review our second quarter results, let me remind you why we're so excited about MASH and why we believe Madrigal is uniquely positioned to lead this market.”
“We've made impressive progress towards our strategic growth priorities to maximize the value of ResDifera and build our pipeline. ResDifera has achieved blockbuster status, generating more than $1.1 billion in net sales in the last 12 months.”
“It's always a great moment of the year to be here. It's, as you said, things are going just great.”
“Today I'll provide an update on the significant momentum we continue to build with the US launch of Rezdiffra. I'll briefly recap the impressive two-year F4c data we shared on our last earnings call, which has since been selected as a late-breaking oral presentation at the EASL Congress in Amsterdam next week.”
Start not stated–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Madrigal Pharmaceuticals, Inc. (MDGL) | President and Chief Executive Officer | $918,531 | $19,206,341 |
| 2024 | Madrigal Pharmaceuticals, Inc. (MDGL) | President and Chief Executive Officer | $889,583 | $12,214,250 |
| 2023 | Madrigal Pharmaceuticals, Inc. (MDGL) | President and Chief Executive Officer | $275,400 | $32,268,400 |
